Clinical Trial Update: Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 clinical trial is evaluating nivolumab added to standard therapy for advanced gastric and esophageal adenocarcinomas, including gastroesophage…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Adenocarcinoma
• Gastric Adenocarcinoma
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• nivolumab (Opdivo) (nivolumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma | Phase 2, Phase 3 | Status: RECRUITING